| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $296,189 | 8 | 100 |
Sells | $0 | 0 | 0 |
| Nichtberger Steven | President & CEO | 1 | $100,778 | 0 | $0 | $100,778 |
| Tomasello Shawn | director | 1 | $50,322 | 0 | $0 | $50,322 |
| Gavel Steve | Chief Commercial Officer | 1 | $50,215 | 0 | $0 | $50,215 |
| Simon Mark | director | 1 | $25,261 | 0 | $0 | $25,261 |
| Binder Gwendolyn | President, Science & Tech. | 1 | $24,763 | 0 | $0 | $24,763 |
| Chang David J. | Chief Medical Officer | 1 | $19,888 | 0 | $0 | $19,888 |
| Gerard Michael | General Counsel | 1 | $14,979 | 0 | $0 | $14,979 |
| Bollard Catherine | director | 1 | $9,982 | 0 | $0 | $9,982 |
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is …
Over the last 12 months, insiders at Cabaletta Bio, Inc. have bought $296,189 and sold $0 worth of Cabaletta Bio, Inc. stock.
On average, over the past 5 years, insiders at Cabaletta Bio, Inc. have bought $319,988 and sold $847,373 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Nichtberger Steven (President & CEO) — $100,778. Tomasello Shawn (director) — $50,322. Gavel Steve (Chief Commercial Officer) — $50,215.
The last purchase of 45,000 shares for transaction amount of $100,778 was made by Nichtberger Steven (President & CEO) on 2026‑01‑21.
| 2026-01-21 | Nichtberger Steven | President & CEO | 45,000 0.0447% | $2.24 | $100,778 | +25.64% | ||
| 2026-01-21 | Simon Mark | director | 11,061 0.0112% | $2.28 | $25,261 | +25.64% | ||
| 2026-01-21 | Binder Gwendolyn | President, Science & Tech. | 11,312 0.011% | $2.19 | $24,763 | +25.64% | ||
| 2026-01-21 | Tomasello Shawn | director | 22,725 0.0223% | $2.21 | $50,322 | +25.64% | ||
| 2026-01-21 | Gavel Steve | Chief Commercial Officer | 22,170 0.0223% | $2.27 | $50,215 | +25.64% | ||
| 2026-01-21 | Chang David J. | Chief Medical Officer | 8,800 0.0088% | $2.26 | $19,888 | +25.64% | ||
| 2026-01-21 | Gerard Michael | General Counsel | 6,600 0.0066% | $2.27 | $14,979 | +25.64% | ||
| 2026-01-21 | Bollard Catherine | director | 4,405 0.0044% | $2.27 | $9,982 | +25.64% | ||
| 2024-01-19 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.026% | $19.59 | $215,439 | -63.58% | |
| 2023-12-19 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.0253% | $21.89 | $240,789 | -62.68% | |
| 2023-11-20 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.0275% | $17.82 | $196,014 | -37.66% | |
| 2023-10-19 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.0279% | $13.36 | $146,921 | -3.03% | |
| 2023-09-19 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.028% | $17.57 | $193,220 | -14.83% | |
| 2023-08-21 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.0273% | $13.42 | $147,583 | +11.34% | |
| 2023-07-19 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.034% | $13.82 | $152,022 | +13.84% | |
| 2023-06-20 | Sale | Binder Gwendolyn | See Remarks | 11,000 0.0342% | $12.99 | $142,925 | +22.08% | |
| 2023-05-19 | Sale | Binder Gwendolyn | See Remarks | 22,000 0.0665% | $11.81 | $259,833 | +30.67% | |
| 2022-10-19 | Nichtberger Steven | President & CEO | 8,127 0.0363% | $1.25 | $10,152 | +753.85% | ||
| 2022-10-18 | Nichtberger Steven | President & CEO | 141,873 0.6605% | $0.99 | $141,008 | +1019.07% | ||
| 2022-10-18 | Simon Mark | director | 125,000 0.572% | $0.98 | $122,121 | +1019.07% |
| Nichtberger Steven | President & CEO | 1031483 0.6084% | $1.46M | 3 | 0 | +886.46% |
| Simon Mark | director | 147205 0.0868% | $209,031.10 | 2 | 0 | +1019.07% |
| Binder Gwendolyn | President, Science & Tech. | 31312 0.0185% | $44,463.04 | 2 | 9 | +1019.07% |
| Tomasello Shawn | director | 22725 0.0134% | $32,269.50 | 1 | 0 | |
| Gavel Steve | Chief Commercial Officer | 22170 0.0131% | $31,481.40 | 1 | 0 | |
| Chang David J. | Chief Medical Officer | 8800 0.0052% | $12,496.00 | 1 | 0 | |
| Gerard Michael | General Counsel | 6600 0.0039% | $9,372.00 | 1 | 0 | |
| Bollard Catherine | director | 5405 0.0032% | $7,675.10 | 2 | 0 | +1019.07% |
| Flynn James E | 10 percent owner | 700000 0.4129% | $994,000.00 | 1 | 0 | +6.66% |
| 5AM Ventures V, L.P. | 10 percent owner | 333144 0.1965% | $473,064.48 | 1 | 5 | +6.66% |
| Marda Anup | Chief Financial Officer | 50000 0.0295% | $71,000.00 | 1 | 0 | +1019.07% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$6,146,922 | 96 | -4.70% | $233.68M | |
$60,836,085 | 69 | 0.45% | $255.44M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$109,019,806 | 28 | 7.37% | $263.86M |
| Increased Positions | 63 | +85.14% | 15M | +21.52% |
| Decreased Positions | 30 | -40.54% | 8M | -11.66% |
| New Positions | 30 | New | 5M | New |
| Sold Out Positions | 10 | Sold Out | 4M | Sold Out |
| Total Postitions | 107 | +44.59% | 76M | +9.87% |
| Bain Capital Life Sciences Investors, Llc | $21,386.00 | 10.08% | 9.68M | 0 | 0% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $19,514.00 | 9.2% | 8.83M | 0 | 0% | 2025-09-30 |
| Jennison Associates Llc | $18,780.00 | 8.85% | 8.5M | +2M | +41.15% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $18,481.00 | 8.71% | 8.36M | +2M | +23.09% | 2025-09-30 |
| Cormorant Asset Management, Lp | $11,050.00 | 5.21% | 5M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $9,262.00 | 4.37% | 4.19M | +740,032 | +21.45% | 2025-09-30 |
| Woodline Partners Lp | $4,719.00 | 2.22% | 2.14M | +916,884 | +75.25% | 2025-09-30 |
| Heights Capital Management, Inc | $4,606.00 | 2.17% | 2.08M | -1M | -33.71% | 2025-09-30 |
| Blackrock, Inc. | $3,582.00 | 1.69% | 1.62M | +650,271 | +67% | 2025-09-30 |
| Superstring Capital Management Lp | $3,413.00 | 1.61% | 1.54M | +483,761 | +45.6% | 2025-09-30 |